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Abstract
Although, the treatment of chronic hepatitis C (CHC) greatly improved with the use of direct
antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many
patients, worldwide. The intra-hepatic level of expression of interferon stimulated genes
(ISGs) and the rs12979860 CC genotype located within IFNL3 have been associated with
sustained virological response (SVR), in patients with CHC. The aim of the study was to
identify micro-RNAs associated with SVR and to build an accurate signature to predict
SVR. Pre-treatment liver biopsies from 111 patients, treated with PEG-IFN plus ribavirin,
were studied. Fifty-seven patients had SVR, 36 non-response (NR) and 18 relapse (RR).
The expression of 851 human miRNAs and 30 selected mRNAs, including ISGs, was as-
sessed by RT-qPCR. In the first group of patients (screen), 20 miRNAs out of the 851 stud-
ied were deregulated between NRs and SVRs. From the 4 miRNAs validated (mir-23a, mir-
181a*, mir-217 and mir-99a), in the second group of patients (validation), 3 (mir-23a, mir-
181a* and mir-99a) were down-regulated in NRs as compared to SVRs. The ISGs, studied,
were accumulated in SVRs and IFNL3 rs12979860 CT/TT carriers compared respectively
to NRs and CC carriers. Combining, clinical data together with the expression of selected
genes and micro-RNAs, we identified a signature (IFI35, mir-99a and HCV genotype) to pre-
dict SVR (AUC:0.876) with a positive predictive value of 86.54% with high sensibility (80%)
and specificity (80.4%). This signature may help to characterize patients with low chance to
respond to PEG-IFN/ribavirin and to elucidate mechanisms of NR.
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Introduction
Hepatitis C virus (HCV) is a major cause of chronic liver disease, with more than 170 million
infected individuals, worldwide [1,2].
The treatment of chronic hepatitis C (CHC) has greatly improved, with the development of
direct antiviral agents (DAAs), reviewed in [3,4]. Whereas interferon-free combinations are very
effective, pegylated-interferon (PEG-IFN) remains an option for a large number of patients
worldwide mainly because of cost issues and access to treatment. Therefore, the prediction of
SVR to IFN based therapy is still highly important to identify (i) patients with high chance to
cure and therefore candidates for this therapy and (ii) those with low chance to respond to
PEG-IFN plus ribavirin, candidates for IFN free therapies. Moreover, the prediction of non-re-
sponse may help to elucidate its molecular mechanisms. The SVR rate is highly associated with
viral factors; patients with genotype 1 and 4 show significantly lower response rate than patients
with genotype 2 and 3. Different liver gene expression profiles have been associated with non-re-
sponse, reviewed in [5]. Interferon stimulated genes (ISGs), have been reported over-expressed,
at baseline, in patients with non-response (NR) compared to sustained virological responders
(SVR) [6–9]. It has been suggested that in patients with high expression of ISGs, at baseline, the
addition of exogenous interferon was not able to activate ISGs expression further [7,9].
Single nucleotide polymorphisms (SNPs), in particular rs12979860, located upstream
IFNL3, were strongly associated with SVR [10,11]. Patients, carrying the favourable geno-
type rs12979860 CC, have higher chance to develop a SVR than patients with CT and TT
genotypes.
Micro-RNAs (miRNAs) are small non-coding RNAs controlling the expression of up to
60% of total mRNAs and therefore are involved in the regulation of major cellular pathways
[12,13].
Both in vitro and in vivomodels showed variation of cellular miRNAs expression upon
HCV infection [14–16]. Moreover, IFNα/β up-regulates several cellular miRNAs (mir-196,
mir-296, mir-351, mir-431, mir-1, mir-30 and mir-128 and mir-448) with putative recognition
sites within HCV genome [17]. Mir-196, mir-296, mir-351, mir-431 and mir-448 were indeed
able to substantially attenuate viral replication [17]. Mir-122 is highly expressed in the liver; its
over-expression stimulates HCV replication, in vitro [18]. The use of anti mir-122 (SPC3649,
miravirsen) inhibits viral replication both in animal model and in HCV infected patients [19–
21]. A reduction of mir-122 expression has been reported, at baseline, in patients with primary
non-response as compared to patients with early virological response [22]. In a previous work,
we showed that mir-122 expression was decreased in patients with IFNL3 CT/TT genotypes
and that this association was stronger than the one between mir-122 and the response to the
treatment [23].
We aimed to identify a specific miRNAs expression profile associated with SVRs and NRs,
in patients with chronic hepatitis C. We studied the expression of liver miRNAs in two inde-
pendent groups of patients (screen and validation groups). We investigated the expression of
validated miRNAS, in serum samples. We built a predictive signature of SVR taking into ac-
count clinical and biological data, IFNL3 rs12979860 genotype and intra-hepatic mRNAs and
miRNAs expression.
Patients and Methods
Characteristics of patients
One hundred eleven patients with CHC, followed at Beaujon Hospital, were consecutively in-
cluded in the study. Pre-treatment percutaneous liver biopsies were collected. The study
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conformed to the ethical guidelines of the 1975 Declaration of Helsinki. All participants pro-
vide their written informed consent to participate in this study.
The patients met the following criteria:
i. an established diagnosis of CHC
ii. the absence of other cause of chronic liver disease and viral co-infection
iii. the patients received a complete treatment of either PEG-IFNα-2b (MSD) at a dose of
1.5 μg/kg/week and weight-based ribavirin at a dose of 800–1200 mg/day, or PEG-IFNα-2a
at a dose of 180 μg/week (Roche) and weight-based ribavirin 1000–1200 mg/day. Duration
of treatment was 48 weeks for HCV genotype 1 and 4 and 24 weeks for genotypes 2 and 3.
For HCV genotype 1 and 4, If HCV-RNA was detectable at 24 weeks of therapy, treatment
was stopped (non response).
iv. the patients had an adequate follow-up: detection of serum HCV RNA by RT-PCR was per-
formed at week 12, week 24, at the end of treatment and and 24 weeks after the end of treat-
ment. SVR was defined as undetectable HCV RNA 24 weeks after completion of treatment,
while NR was defined as detectable serum HCV RNA at the end of the treatment [24,25].
Responder-relapsers (RR) was defined as the reappearance of detectable serum HCV RNA
within 24 weeks, after treatment cessation in patients with no detectable serum HCV RNA
at the end of treatment [24,25]. All the patients included in this study had an
excellent compliance.
A total of 111 patients were included in two independent groups (Table 1): the screen group
(n = 28; 14 NRs and 14 SVRs) and the validation group (n = 83; 42 SVRs, 22 NRs and 18 RRs).
The differential expression of the 851 human miRNAs in NRs and SVRs was assessed in the
screen group, therefore the same number of patients with SVR and NR were included. Liver bi-
opsies from the validation group (n = 83; 42 SVRs, 22 NRs and 18 RRs) were used in an inde-
pendent set of experiments, to confirm the results. We enlarged the population with SVRs,
NRs and RRs, in accordance with real life data. The expression of the validated mRNAS was as-
sessed in available serum samples from 68 patients of our cohort. The 20 miRNAs deregulated
in the screen group (showing at least a 2-fold difference between NRs and SVRs) were studied
independently in the validation group.
A selective analysis was performed in the total group of 111 patients. The aim was to study
the expression of 6 miRNAs (mir-122, mir-196b, mir-296-5p, mir-448, mir-431 and mir-218)
and 30 mRNAs (S1 Table). While the 6 miRNAs were previously associated with HCV infec-
tion [17,18], the 30 selected genes were mainly involved in IFN signalling, cell adhesion and
cell junction or encoding growth factors (S1 Table) [26,27]. Using liver biopsies, the fibrosis
was staged according to the METAVIR scoring system: F0, no fibrosis; F1, portal fibrosis with-
out septa; F2, portal fibrosis with rare septa; F3, numerous septa without cirrhosis; F4, cirrhosis
[28].
Histologically normal controls
Percutaneous liver biopsy specimens were taken from 9 adults with mild elevation of alanine
aminotransferase (ALT) with no cause of liver disease (medication, alcohol, chronic viral hepa-
titis, autoimmune processes and metabolic disease) [29]. All the specimens were histologically
normal with absence of inflammation, fibrosis, pathological pattern and less than 5% steatosis.
Micro-RNAs and Response in Chronic Hepatitis C
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IFNL3 genotyping
The patients were genotyped for rs12979860 using direct sequencing (Applied Biosystems), as
previously described [10]. Primers used are available on request. Free circulating DNA was ex-
tracted from 500μl serum sample (Qiagen). The PCR products were separated on an ABI3130
sequencer, and analysed with SEQSCAPE 2.6 (Applied Biosystems).
Statistical analysis
As the miRNA and mRNA levels did not fit a Gaussian distribution, (a) both the miRNA and
mRNA levels in each subgroup of samples were characterized by their median values and
ranges, rather than their mean values and coefficients of variation, and (b) relationships
Table 1. Characteristics of the patients.
Variable Screen Validation Total SVR/NR Pvaluesb
n 28 83 111
Gender: male (%) / female (%) 14(50) / 14 (50) 56 (67) /27 (33) 70 (63) / 41 (37) 0.1315
Age [mean ± SD (range)] 50.5 ± 7.5 (34–68) 46.6 ± 9.1 (28–73) 47.1 ± 8.9 (28–73)
BMI, kg.m-2 [mean ± SD (range)] 25.08 ± 3.64 (19.37–
33.05)
25.49 ± 4.21 (17.64–
37.83)
25.45 ± 4.19 (17.64–
37.83)
0.0967
Alanine minotransferase (ALT) IU/L
[mean ± SD (range)]
103.0 ± 97.9 (20–
352)
107.1 ± 67.1 (18–
459)
105.1 ± 72.5 (18–
459)
0.5508
Aspartate aminotransferase (AST) IU/L
[mean ± SD (range)]
65.0 ± 57.6 (25–233) 63.87 ± 35.49 (21–
323)
64.07 ± 34.80 (21–
323)
0.1565
Gamma-glutamyltransferase (GGT) IU/L
[mean ± SD (range)]
64.73 ± 90.78 (3–
315)
90.31 ± 86.27 (7–
411)
84.98 ± 87.20 (4–
411)
0.0040
Total-cholesterol mmol/L [mean ± SD
(range)]
4.80 ± 0.77 (3.43–
6.49)
4.70 ± 0.92 (3.11–
7.36)
4.73 ± 0.87 (3.11–
7.36)
0.0829
Glycemia mmol/L [mean ± SD (range)] 5.0 ± 0.63 (3.2–6.3) 5.40 ± 1.50 (3.14–
13.6)
5.2 ± 1.31 (3.2–13.6) 0.9353
Viral loads: copies per mL [median
(range)]
4.63.106 (1.4.104–
2.73.107)
1.87.106 (3.103–
3.06.107)
2.97.106 (3.103–
3.06.107)
0.0032
HCV genotypes, n(%) 1 19 (68) 38 (46) 57 (51.2) 1 vs. 2,3,5,6 0.0029
2 3 (10.5) 9 (10.5) 12 (10.8)
3 1 (3.5) 13 (15.5) 14 (13)
4 4 (14.5) 22 (26.5) 26 (23.2)
5 1 (3.5) 1 (1.5) 1 (0.9)
6 1 (1.5) 1 (0.9)
IFNL3 rs12979860 polymorphism, n(%) C/C 11 (39.3) 20 (24.1) 31 (28) CT vs. CC 0.2634 TT
vs. CC 0.0062C/T 7 (25) 33 (39.8) 40 (36)
T/T 8 (28.6) 19 (22.9) 27 (24.3)
Fibrosis Score (Metavir), n(%) 1 11 (39.2) 23 (27.7) 34 (30.6) 0.5835
2 16 (57.2) 24 (28.9) 40 (36.1)
3 1 (3.6) 17 (20.5) 18 (16.2)
4 17 (20.5) 17 (15.3)
unknown 2 (2.4) 2 (1.8)
Treatment response, n(%)a SVR 14 (50) 43 (52) 57 (51.2)
NR 14 (50) 22 (26.5) 36 (32.4)
RR 18 (21.5) 18 (16.2)
aResults are expressed as mean ± SD (range). NRs, non-responders; SVRs, sustained virological responders; RRs, responder–relapsers.
b statistical assessment of each variable in NRs and SVRs in the total group.
doi:10.1371/journal.pone.0121395.t001
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between the molecular markers and histological and viral parameters were tested using the
nonparametric Mann–Whitney U test (Mann and Whitney, 1947). For miRNAs, differences
between two populations were judged significant at confidence levels greater than 95%
(p< 0.05) and a fold between the two populations more than 2 or a confidence level greater
than 99% (p<0.01).
The selected miRNAs were assessed in the validation sample (excluding patients who were
RR) using the same methodology. Deregulated miRNAs identified at this validation stage were
candidate covariates for further analysis.
To identify independent predictors of SVR, we performed logistic regression modelling
comparing NRs and SVRs in the total group (screen + validation, excluding RR patients). We
performed univariate analyses to test the association between each candidate covariate and the
response using the Wald test and we calculated the associated odds-ratios (OR). Covariates
with a p-value<0.05 were selected for further multivariate analysis. In multivariate analysis a
backward selection strategy was used to select independent predictors. The performance of the
predictive selected model was assessed using the area under the receiver operating characteris-
tic (ROC) curve. We used bootstrapping with 1,000 replicates of the total sample for internal
validation of the predictive performance of the model as described in a previous study [30].
The material and methods of the RNA extraction and the RT-q-PCR are detailed in the S1
Methods.
Results
Patients
Baseline characteristics of the 111 patients studied are presented in Table 1. Patients are mainly
male (n = 70 in the total group). The mean age at liver biopsy was 47.1 years. Genotypes were
represented as follows with 51.2%, 10.8%, 13% and 23.2% of patients with respectively geno-
types 1, 2, 3 and 4, in the total group of patients. Genotypes 1 and 4 are the most frequent in pa-
tients followed at Beaujon Hospital.
Patients from the screen group (n = 28) had mainly mild (F1) (n = 11) and moderate (F2) fi-
brosis (n = 16). In the screen group, patients with more advanced fibrosis were excluded to
avoid identification of miRNAs that may be rather associated with advanced fibrosis than with
response to PEG-IFN plus ribavirin. In the validation group, 23, 24, 17 and 17 patients were re-
spectively F1, F2, F3 and F4. The fibrosis stage was unknown for 2 patients. Out of the 111 pa-
tients, 57 were SVR, 36 NR and 18 RR.
In the total group (excluding RR patients), Gamma-glutamyltransferase (per IU/L increase,
OR = 0.991; 95% CI: 0.986–0.997; p = 0.0040), HCV viral load (per log10 cp/ml increase,
OR = 0.311; 95% CI: 0.145–0.675; p = 0.0032) and HVC genotype 1 (vs. others, OR = 0.093;
95% CI: 0.020–0.444; p = 0.0029) were associated with lower rates of SVR. Moreover, IFNL3
rs12979860 TT genotype was associated with NR (vs. CC or CT, OR = 0.271; 95%:CI 0.101–
0.729; p = 0.0097).
MiRNAs expression
Global miRNA approach. Out of the 851 miRNAs studied, 20 were particularly deregu-
lated (confidence levels greater than 95% (p< 0.05) and a fold between the two population
more than 2 or a confidence level greater than 99% (p<0.01) between NRs and SVRs, in the
screen group) (Fig. 1A and Table 2A). Four out of the 20 miRNAs selected showed the same
deregulation of expression in the screen group and the validation group (Fig. 1B and Table 2B).
Mir-99a, mir-181a and mir-23a were down-regulated in NRs whereas mir-217 was accumu-
lated in NRs compared to SVRs.
Micro-RNAs and Response in Chronic Hepatitis C
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The OR were calculated for each of the 4 miRNAs, 3 were statistically significant (mir-99a,
mir-181a and mir-23a) (Fig. 2). The AUC of the model consisting in the combination of mir-
99a, mir-181a and mir-23a was 0.7346 (Fig. 2A). The sensibility, specificity, positive predictive
value and negative predictive value of each miRNAs and the model combining the 3 miRNAs
are represented on Fig. 2B.
Candidate miRNAs approach. In our study, mir-122 was neither significantly decreased
in NRs compared to SVRs in the screen group (p = 0.077) nor in the total group (p = 0.06)
(Fig. 2C). None of the miRNAs regulating HCV replication in vitro (mir-196b p = 0.499, mir-
296-5p p = 0.253, mir-431 p = 0.128, mir-448 p = 0.971) showed difference of expression prior
to treatment, in NRs and SVRs (Fig. 2C). The expression of mir-296-5p (p = 0.002), mir-122
(p<0.001), mir-448 (p<0.001) and mir-128 (p<0.001) was significantly down-regulated in pa-
tients with chronic hepatitis C compared to normal non-infected patients (Fig. 2C).
The expression of mir-23a, mir-99a, mir-181a, mir-217 and mir-122 was investigated, in
68 serum samples available (NR = 26, RR = 10, RR = 32) (Fig. 3). The level of expression of
mir-23a and mir-99a were low compared to mir-122 (Fig. 3A). None of mir-23a, mir-99a and
mir-122 was differentially expressed between SVRs and NRs (Fig. 3A). Interestingly, only
serum mir-122 and alanine amino transferase were strongly correlated (Fig. 3B), as we previ-
ously described [23]. Mir-217 and mir-181a were not detected efficiently in our serum sam-
ples (Fig. 3). Moreover, the expression of mir-23a, mir-99a and mir-122 were not correlated in
serum and liver samples (Table 3).
Modification of mRNAs expression in NRs and SVRs
From the 30 mRNAs tested 25 were deregulated between NRs and SVRs (Fig. 4A and Table 4).
Interestingly all the ISGs assessed were accumulated in NRs compared to SVRs (Fig. 4A and
Table 4). The ORs were calculated for each mRNAs (Table 4).
ISGs were particularly over-expressed in rs12979860 TT (16.125 to 2.07 fold Fig. 4B and
S2A and S2B Tables) patients compared to CC (Fig. 4B). The 3 co-receptors of HCV entry
occludin (OCLN) CD81 molecule (CD81) and claudin 1 (CLDN1) were only accumulated in
NRs compared to SVRs and not in IFNL3 TT compared to CC patients (Table 4 and S2 Table).
Design of a signature to predict SVR
The clinical and biological data, IFNL3 polymorphism, mRNAs and miRNAs expression were
analyzed by multivariate analysis. IFNL3 polymorphism was not independent of ISGs expres-
sion (S3 Table). ISGs were particularly over-expressed in NRs compared to SVRs. It is likely
that ISGs expression is a stronger predictor than IFNL3 SNPs, considering the results of multi-
variate analysis. Mir-99a (per unit of relative mir-99a expression increase OR = 6.053 95% CI:
1.897–19.314 p = 0.0024) IFI35 (per unit of relative IFI35 expression increase OR = 0.069 95%
CI:0.013–0.361 p = 0.0015) and HCV genotype 1 (vs. other genotypes OR = 0.093 95% CI:
0.020–0.444 p = 0.0029) were combined in a model predictor of SVR (Fig. 5A). The details
about the selection of the variables in the multivariate analysis are presented in S3 Table. Over-
all the variables included in the multivariate analysis only mir-99a, IFI35 and HCV genotype 1
were independent predictors of SVR (p = 0.0051 p = 0.0011 and p = 0.0059 respectively Wald
test) (Fig. 5B). Interestingly the model predicts SVR with a positive predictive value of 86.54%
(and a negative predictive value of 71.8%), a sensibility of 80% and a specificity of 80.4%. In pa-
tients infected with genotype 1 both IFI35 and mir-99a expression were important to predict
SVR. However, in patients infected with either genotype 2, 3, 4 or 5, IFI35 expression alone was
a predictor of SVR (Fig. 5C).
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Fig 1. Modification of miRNAs expression in SVRs and NRs. Total RNAs was extracted and analyzed for miRNAs content by RT q-PCR. The ΔCt for
each miRNA was calculated and normalized to the ΔCt value of SNORD44, in each biopsy. The histograms represent the mean expression of miRNAs/
SNORD44 within the groups of patients NRs, SVRs and RRs normalized to the expression of the same miRNA within the group of normal patients. The
Micro-RNAs and Response in Chronic Hepatitis C
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For the identification of mir-99a, in the screen group, we use of a validation procedure on
an independent sample prevented inflation of type I error and false discovery rate. A simple
calculation under the hypothesis that all 20 miRNAs detected in the screening stage were false
positive findings (a conservative scenario) showed that the likelihood of 4 (or more) false posi-
tive results on the validation sample (using a type I error at 5%) was 1.6%. In other words, it
was unlikely to observe 4 miRNAs detected on the validation stage if all miRNAs detected on
the test stage were false positive. Further analysis showed that only mir-99a was an indepen-
dent predictor of SVR and mir-99a was integrated in the signature to predict SVR, with a p-
Value of 0.0051 in multivariate analysis. We are confident that this result is unlikely related to
inflation of type I error. However, further analysis will be needed to confirm the role of mir-
99a in the prediction of SVR.
Discussion
Identification of miRNAs associated with SVR
The major novelty of our work consists in the identification of 4 miRNAs (mir-23a, mir-99a,
mir-181a, and mir-217) differentially expressed between NRs and SVRs.
The expression of mir-23a, mir-99a and mir-181a was increased in SVRs compared to
NRs. However, mir-217 was reduced in SVRs compared to NRs. Previous reports described
association of miRNAs expression with viral response was calculated using the Wald test. 1A- Out of 851 miRNAs, 20 miRNAs were particularly deregulated
between NRs and SVRs in the screen group (p<0.05 with at least a 2-fold difference between NRs and SVRs or p<0.01). 1B- The expression of the 20
miRNAs previously selected was assessed by RT q-PCR, in the validation group, independently. N = normal non-infected patients, NR = non-responders,
RR = responders-relapsers, SVR = sustained virological responders.
doi:10.1371/journal.pone.0121395.g001
Table 2. Differentially expressedmiRNAs between NRs, SVRs and RR, prior to treatment.
Screen Validation
miRNAS NR SVR pvalue NR SVR RR pvalue
mir-455-3p 0.211 0.498 0.002 0.168 0.213 0.171 0.44
mir-20a* 0.202 0.415 0.009 0.343 0.406 0.355 0.81
mir-624* 0.330 0.672 0.006 0.357 0.410 0.269 0.16
mir-616 0.450 0.904 0.044 0.374 0.351 0.246 0.39
mir-29b 0.244 0.482 0.011 0.356 0.276 0.211 0.30
mir-19a 0.155 0.301 0.025 0.092 0.101 0.057 0.80
mir-99a 0.223 0.412 0.002 0.343 0.478 0.295 0.0382
mir-148a 0.238 0.424 0.000 0.258 0.361 0.224 0.19
mir-28 0.344 0.581 0.004 0.411 0.497 0.389 0.31
mir30a-5p 0.317 0.487 0.005 0.375 0.352 0.259 0.98
mir-30b 0.568 0.870 0.011 0.312 0.412 0.244 0.53
mir-744 0.449 0.676 0.008 0.422 0.534 0.448 0.30
mir-30e 0.251 0.371 0.004 0.367 0.374 0.282 0.91
mir-181a* 0.400 0.591 0.005 0.522 0.622 0.486 0.0423
mir-576_5p 0.568 0.772 0.008 0.600 0.697 0.510 0.28
mir-23a 0.602 0.763 0.008 0.558 0.804 0.689 0.009
mir-200b* 1.491 0.891 0.005 1.385 1.424 1.619 0.51
mir-200b 3.985 1.986 0.024 2.471 2.035 2.604 0.23
mir-217 2.043 0.770 0.021 5.932 2.042 2.585 0.031
mir-886-3p 6.899 2.474 0.004 2.081 1.025 0.923 0.1222
doi:10.1371/journal.pone.0121395.t002
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Fig 2. Identification of a 3 miRNAs signature (mir-99a, mir-23a andmir-181a*) predictor of SVR and
selective analysis of miRNAs expression in NRs and SVRs. 2A- The receiver Operator Curves (ROC)
were calculated for each miRNAs and for the signature based on the combination of the 3 miRNAs. 2B- The
Micro-RNAs and Response in Chronic Hepatitis C
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hepatic expression of mir-99a, mir-23a and mir-181a suggesting processing of the pre-Mir and
co-expression of mir-181a [31–33]. Interestingly, in malignant cells, whereas the expression of
some miRNAs is increased, the widespread under-expression of miRNAs is a more common
phenomenon [34]. The modification of miRNAs expression profile might suggest that in NRs,
hepatic cells may be more likely to undergo malignant process than in SVRs.
Interestingly, Mir-217 has been described as an oncogene [35] and a reduction of mir-99a
expression has been reported in HCC tissues [31]. Moreover, restoration of mir-99a, in vitro,
dramatically suppressed HCC cell growth by inducing G1 phase cell cycle arrest [31]. Mir-99a
is increased during TGFB-induced epithelial to mesenchymal transition (EMT) [36]. Since
EMT is involved during liver fibrogenesis, the expression of mir-99a may increase during fibro-
sis. Surprisingly, in our cohort, the expression of mir-99a is reduced in F2-F4 vs. F1 (p = 0.028)
and in F3-F4 vs. F1F2 (p = 0.035) (S1 Fig). The EMT, in the liver may not induce a reduction of
mir-99a expression. The reduction of mir-99a in NRs and at later stages of fibrosis may indi-
cate that these two groups of patients have a higher risk to develop HCC.
The over-expression of mir-23a has been described in mouse models developing non-alco-
holic steato-hepatitis, and HCC [32]. Moreover, mir-23a down-regulates interleukin-6 receptor
[37] whereas high level of circulating IL-6 has been associated with NR [38]. The modulation
of mir23a expression may regulate IL6 signalling in patients with CHC.
Interestingly, hepatic mir-181a was up regulated in patients with SVR compared to NRs
after PEG-IFN/RBV therapy [39]. This result supports our data and strongly suggest an up-reg-
ulation of mir-181a expression in patients with SVRs.
Only few putative mRNAs targets of mir-23a, mir-217, mir-99a and mir-181a have been
described, so far. A deeper analysis of these miRNAs activity may help to elucidate the mecha-
nisms of NR to IFN-based therapy.
A previous study investigating the modification of miRNAs expression, didn’t report the
same set of miRNAs associated with SVR [16]. However, the authors didn’t validate their re-
sults using an independent group of patients and included only patients with Japanese ancestry
[16]. These discrepancies may explain the identification of different miRNAs associated with
SVR.
Mir-122 showed a trend of down-regulation in NRs. In a previous work, we reported a re-
duction of mir-122 in NRs plus RRs as compared to SVRs patients [23]. In agreement, in the
current cohort, when RRs were added to the group of NRs, the difference of mir-122 expression
between SVRs and NRs plus RRs was statistically significant (p = 0.02).
MiR-196, miR-296-5p, miR-431 and miR-448 are all induced by IFN α/β and contain puta-
tive recognition sites within HCV genome [17]. Whereas ISGs were significantly accumulated
in NRs, no difference of expression of IFN-induced miRNAs was observed. Interestingly, this
data raises the hypothesis that activation of miRNAs induced by IFN and ISGs, in NRs, may in-
volve different signalling pathways.
In the serum, the level of expression of mir-23a and mir-99a were low compared to the one
of mir-122 (Fig. 3A). Interestingly, serum mir-99a was down-regulated in patients with HCV
sensibility (Se), specificity (Spe), positive predictive value (PPV) and negative predictive value (NPV) were
calculated for each miRNA isolated and for the combination of the 3 miRNAs. 2C- The expression of mir-122,
mir-196b, mir-296-5p, mir-448, mir-431 and mir-128 was analyzed by RT q-PCR in the total group of patients
(n = 111). The ΔCp (ΔCpt = 2
ΔCpsample) for each miRNAs was calculated and normalized to the ΔCp value of
SNORD44 in each biopsy. The histograms represent the mean expression of miRNA/SNORD44 within the
groups of patients NRs, SVRs and RRs normalized to the expression of the samemiRNA within the group of
normal patients. The association of mRNAs expression with viral response was calculated using theWald
test. N = normal un-infected patients, NR = non-responders, RR = responders-relapsers, SVR = sustained
virological responders.
doi:10.1371/journal.pone.0121395.g002
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Fig 3. Modification of miRNAs expression in the serum of patients with chronic hepatitis C. 3A- Mir-23a, mir-99a, mir-181a*, mir-217 and mir-122 were
detected by RT-q-PCR in 68 serums (NR = 26, RR = 10, RR = 32). The ΔCt for each miRNAs were calculated and normalized to the ΔCt value of c.elegans
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compared to normal controls and patients with chronic hepatitis B [40]. This discrepancy may
explain the low level of serum mir-99a detected in our cohort. Circulating mir-23a was sug-
gested to be associated with type 2 diabetes [41]. However, in our cohort, none of the patients
for whom serum was available, had diabetes. So we were unable to investigate this association.
Interestingly, mir-122 was expressed in the serum and strongly correlates with Alanine amino
transferase (Fig. 3B), confirming our previous results [23]. The levels of expression of mir-217
and mir-181a were too low to be detected efficiently (Fig. 3A). To our knowledge, there are no
study that reported efficient detection of serum mir-217 and mir-181a in human serum
samples.
Analysis of mRNAs associated with response
All the ISGs studied were over-expressed in NRs, prior to treatment (Fig. 4A and Table 4).
IFI35 is involved in the antiviral functions of IFN against viral infections. The over-expression
of IFI35 suppresses the activation of IFNβ and ISG56 promoters [42]. Interestingly, in patients
with NR, the higher expression of IFI35 may limit the efficacy of PEG-IFN to activate the ex-
pression of ISGs.
An interesting additional finding was the association of ISGs expression with the unfavour-
able T allele of rs12979860 IFNL3 (Fig. 4B and S2A and S2B Tables), as it was previously de-
scribed [43–45]. Several studies reported that intra-hepatic ISGs expression is a better
predictor of SVR than IFNL3 polymorphisms [44,45]. The expression of a set of 3 ISGs (ISG15,
IFI27 and IFI6) has been associated with rs12979860 SNPs [46]. IFNL3 polymorphisms have
been suggested to be associated with a specific cell-type modulation of ISGs expression (MxA,
PKR, OAS1 and ISG15) in hepatic cells and PBMCs [43].
Predictive signature of SVR
We identified a signature combining the hepatic expression 3 miRNAs (mir-23a, mir-99a and
mir-181a) to predict SVR (AUC: 0.7346) (Fig. 2A). In our study, the accumulation of intra-he-
patic ISGs expression, prior to treatment was more highly associated with NR than with IFNL3
rs12979860 TT genotype. The multivariate analysis of all clinical and biological data, miRNAs
mir-39. The histograms represent the mean expression of miRNAs/mir-39 within the groups of patients NRs, RRs and SVRs. 3B- Correlation between mir-
122 and alanine amino transferase, in the serum. The correlation was assessed using the Spearman correlation test. NR = non-responders,
RR = responders-relapsers, SVR = sustained virological responders.
doi:10.1371/journal.pone.0121395.g003
Table 3. Correlation between hepatic and serum expression of miRNAs.
mir-23a R Pearson -0.197
pvalue 0.325
mir-99a R Pearson -0.370
pvalue 0.090
mir-181a* R Pearson 0.293
p value 0.573
mir-217 R Pearson NA*
p value NA*
mir-122 R Pearson 0.038
p value 0.781
*NA: not applicable.
doi:10.1371/journal.pone.0121395.t003
Micro-RNAs and Response in Chronic Hepatitis C
PLOS ONE | DOI:10.1371/journal.pone.0121395 April 6, 2015 12 / 19
Fig 4. Differential mRNAs expression in NRs and SVRs prior to treatment. 4A- The hepatic expression of 25 mRNAs was assessed in the total group of
patients by RT q-PCR. The ΔCp (ΔCpt = 2
ΔCpsample) value was calculated for each mRNA expression and normalized to the ΔCp value of RPLP0 in each liver
biopsy. The histograms represent the mean value of the expression of mRNA in NRs, SVRs and RRs. The expression values were compared by non-
parametric test. 4B- High expression of ISGs is associated with IFNL3 TT genotype. The intra-hepatic expression of 25 mRNAs was analyzed by RT-qPCR
Micro-RNAs and Response in Chronic Hepatitis C
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and mRNAs expression and IFNL3 SNPs, allowed us to build a signature (IFI35, mir-99a and
HCV genotype) which is associated with a high predictive positive value (86.54%), sensibility
(80%) and specificity (80.4%). None of the miRNAs identified showed a correlation between its
hepatic and its serum expression (Table 3). Therefore, the expression of mir-99a alone or both
mir-23a, mir-99a and mir-181a has to be assessed in the liver, to provide enough information
to predict SVR.
In a multivariable regression model, studying a HCV genotype 1 cohort, IFNL3 rs12979860
CC genotype was the strongest pre-treatment predictor of SVR (OR = 5.2; 95% CI: 4.1–6.7)
from total RNAs extracts. IFNL3 rs12979860 polymorphism was determined by direct sequencing. The ΔCp (ΔCpt = 2
ΔCpsample) value was calculated for
each mRNA expression and normalized to the ΔCp value of RPLP0 in each liver biopsy. The histograms represent the mean value of the ratio of each mRNA
expression in TT + CT /CC patients. ISGs: Interferon stimulated genes non- ISGs: other type of genes. NR = non-responders, RR = responders-relapsers,
SVR = sustained virological responders.
doi:10.1371/journal.pone.0121395.g004
Table 4. Differentially expressedmRNAs between NRs and SVRs in patients with CHC prior to treatment.
mRNAs ORa 95 % CIb pvalue
1-GIP2 0.818 0.711–0.940 0.0047
2-GIP3 0.035 0.003–0.358 0.0048
3-HERC5 0.300 0.130–0.695 0.0050
4-IFI27 0.612 0.470–0.798 0.0003
5-IFI35 0.069 0.013–0.361 0.0015
6-IFI44 0.048 0.005–0.466 0.0088
7-IFIT1 <0.001 <0.001–0.004 0.0028
8-IFIT4 0.745 0.544–1.019 0.0653
9-IFITM1 0.266 0.100–0.711 0.0083
10-LGALS3BP 0.004 <0.001–0.172 0.0039
11-MIX1 0.843 0.742–0.957 0.0082
12-OAS1 0.656 0.492–0.875 0.0041
13-OAS2 0.591 0.268–1.306 0.1934
14-OAS3 0.765 0.626–0.934 0.0086
15-PLSCR1 0.327 0.147–0.729 0.0062
16-PSMB9 0.046 0.010–0.213 <.0001
17-RSAD2 0.761 0.590–0.983 0.0368
18-STAT1 0.139 0.036–0.537 0.0042
19-USP18 0.581 0.397–0.849 0.0051
20-CCL21 <0.001 <0.001 - <0.001 0.0032
21-CD81 1.282 0.792–2.076 0.3125
22-CLDN1 0.523 0.360–0.760 0.0007
23-CXCL9 1.133 0.425–3.017 0.8027
24-CXCL10 0.014 <0.001–0.324 0.0077
25-CXCL11 0.371 0.183–0.751 0.0059
26-IL8 0.711 0.514–0.982 0.0382
27-ITGA2 0.159 0.045–0.565 0.0045
28-MDK 0.005 <0.001–0.159 0.0030
29-OCLN <0.001 <0.001 - <0.001 0.0070
30-STMN2 0.935 0.777–1.124 0.4730
a Odds ratio;
b 95% Conﬁdence Interval
doi:10.1371/journal.pone.0121395.t004
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with only a sensitivity of 56%, a specificity of 79%, a positive predictive value of 69% and a neg-
ative predictive value of 68% [47]. Accordingly, in our cohort, IFNL3 alone showed only mod-
erate accuracy to predict SVR. The predictive value of IFNL3 polymorphism is stronger in
HCV genotypes 1 and 4 than in genotypes 2 and 3 [10,48]. Therefore, in our cohort combining
all genotypes, the accuracy of IFNL3may be reduced. The combination of mir-99a, IFI35 ex-
pression and HCV genotype was a higher predictive factor, at baseline, than IFNL3 polymor-
phism (Fig. 5).
Fig 5. Identification of a signature predicting SVR. Clinical, miRNAs and mRNAs expression data were analyzed by multivariate analysis. 5A- ORs are
presented for the 3 variables of the signature: mir-99a, IFI35 and HCV genotype 1. 5B- Receiver Operator Curves for prediction of viral response of the
signature (AUC 0.876) (genotype 1, IFI35 and mir-99a expression) based on IFI35 expression (AUC 0.777) and mir-99a (AUC 0.688). 5C- Schematic
representation of the prediction of SVR. Patients with genotype non-1 had high SVR rates when they express low level of IFI35 (l for low,<mean IFI35
expression). HCV genotype 1 infected patients with low level of IFI35 and high level of mir-99a (h for high,>mean mir-99a expression) showed high
SVR rates.
doi:10.1371/journal.pone.0121395.g005
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In the current cohort (111 patients) both the 3-miRNAs-signature (AUC = 0.74) and the
multi-variable signature (AUC = 0.876) showed higher accuracy to predict SVR than the
2-ISGs-signature (IFI27 and CXCL9) previously described by our group (AUC = 0.713) [6].
An independent study reported a 4-ISGs-signature (IFI27, GIP3/ISG15, RSAD2 and HTA-
TIP2) as stronger predictor of SVR than IFNL3 SNPs [44]. However, the authors only investi-
gated the expression of 8 selected mRNAs in a single group of patients without any validation
set [44].
Whereas major improvements have been achieved in the treatment of CHC with the devel-
opment of DAAs, PEG-IFN and ribavirin remains an option for many patients worldwide.
Therefore the prediction of responsiveness to PEG-IFN plus ribavirin remains an important
issue. The assessment of the hepatic expression of mir-99a and IFI35 may help to discriminate
patients with low chance to respond to PEG-IFN plus ribavirin. In clinical practice, performing
a liver biopsy remains useful to stage fibrosis [49], since urgent initiation of treatment is recom-
mended for patients with advanced fibrosis or compensated cirrhosis. Performing different
tests (stage fibrosis and predict treatment response) on the same liver biopsy could optimize
the use of this invasive procedure. Patients with low chance to respond to PEG-IFN plus ribavi-
rin may be candidates for IFN-free regimen.
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